Application of Patuzumab and Trastuzumab in Breast Cancer Patients with Positive Human Epidermal Growth Factor Receptor 2
Objective To analyze the effect of combined treatment of patuzumab and trastuzumab in breast cancer patients with positive human epidermal growth factor receptor 2(HER2).Methods Eighty patients with HER2-positive breast cancer admitted to the hospital from May 2020 to April 2023 were selected as the study objects,and were divided into a control group and a study group according to random number table method,with 40 cases each.Both groups received conventional neoadjuvant chemotherapy,the control group was treated with trastuzumab,and the study group was treated with pertuzumab based on the control group.Objective response rate,levels of carbohydrate antigen 153(CA153)and carcinoembryonic antigen(CEA)and occurrence of adverse reactions were compared between the two groups.Results The objective remission rate of the study group was 87.50%,higher than 67.50% of the control group,the difference was statistically significant(P﹤0.05).After treatment,CEA and CA153 levels in two groups were lower than before treatment,and the study group was lower than the control group,the differences were statistically significant(P﹤0.05).There were no significant differences in the incidence of allergic reaction,gastrointestinal reaction,abnormal blood system,neurotoxicity and liver and kidney injury between the two groups(P﹥0.05).Conclusion Trastuzumab and Partuzumab can improve the objective remission rate of breast cancer HER2 positive,inhibit serum tumor markers,and have clinical application value.
Breast cancerHuman epidermal growth factor receptor 2TrastuzumabPatuzumab
NETL
NSTL
万方数据
